There are three types of Antigen Presenting Cells:
• Macrophages
• Dendritic Cells
• B Cells
We will focus our attention on the Dendritic cells (DCs ) because I postulate that these cells played a major roll in help generating an immune response. Induced Dendritic cells go through a developental program call maturation, which transforms them into efficient antigen-presenting cells (APCs) and T-cell activators. They are the most potent of the three APCs.
So what really happened? Well, Dr. Kirkwood started me out on Dacarbazine with PaTrin-2. Dacarbazine is a chemotherapy agent, approved by the FDA for fighting Melanoma. Dacarbazine alkylates and cross-links DNA during the phases of the cell cycle, resulting in disruption of DNA function, causing cell cycle arrest, and apoptosis.17 The only problem is that the Melanoma Cells overexpresses this enzyme called MGMT.
Proteins known as DNA repair enzymes are present in cells to target damaged DNA and reverse the modifications caused by alkylating agents. One such enzyme is methylguanine methyltransferase (MGMT). MGMT directly reverses the chemical modification guanine, one of the four building blocks of DNA, allowing normal replication to take place.
The DNA-repair enzyme MGMT is a key factor in resistance to alkylating agents. This is one reason why the Dacarbazine therapy doesn’t have a very successful response rate. The MGMT enzyme repairs what the dacarbazine cross-links. So, PaTrin-2 was added to the trial. This drug is known to inactivate the MGMT activity. By inactivating the MGMT enzyme, it makes the tumors cells more susceptible to the chemotherapy.
This therapy was able to get the tumors cells to shed some antigenic Protein which I theorize and was used as the presenting antigen. This made the antigen “tumor-specific.”
Base on a paper by Dr. Olivera J.Finn called Cancer Immunology published in the New England Journal of Medicine in June 19, 2008, there are three ways for self antigens to become Tumor Antigens:
1. Mutation
2. over expression
3. Post-translational Modification
I postulate that some failure of the tumor cells to repair the DNA damage cause by the Dacarbazine in the present of PaTrin-2 resulted in a mutation causing the cancer cells to shed an antigenic peptide.
Well there is also anther protein that is overexpress in the cancer cells. It is the Bcl-2 protein. Bcl-2 has been implicated in disease resistance.
There is now a drug called Genasense®. Based on the clinical results. It also helps shed the right antigen. (The tumor-specific antigen)
Genasense®
If I am reading the data correctly, it is telling us that it to can be used with (DTIC) Dacarbazine to shed some antigenic protein. So If you combine the two, you are most likely will have the right antigen to present.
source:http://mct.aacrjournals.org/content/3/10/1215.abstract?ck=nck
Molecular Cancer Therapeutics
Take Care,
Jimmy B
No comments:
Post a Comment